BioAge Labs, Inc. (BIOA)
BioAge Labs will go public soon. The estimated IPO date is September 26, 2024.
IPO Price
$18.00
Shares Offered
11,000,000
Deal Size
$198.00M
BioAge Labs Statistics
Total Valuation
BioAge Labs has a market cap or net worth of $619.41 million. The enterprise value is $472.04 million.
Market Cap | 619.41M |
Enterprise Value | 472.04M |
Important Dates
Earnings Date | n/a |
Ex-Dividend Date | n/a |
Share Statistics
BioAge Labs has 34.41 million shares outstanding.
Shares Outstanding | 34.41M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | n/a |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
Current Ratio | n/a |
Quick Ratio | n/a |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -26.66 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | n/a |
Return on Capital (ROIC) | n/a |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.04M |
Employee Count | 60 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (5Y) | n/a |
52-Week Price Change | n/a |
50-Day Moving Average | n/a |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | n/a |
Average Volume (20 Days) | n/a |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -51.57M |
Pretax Income | -62.16M |
Net Income | -62.16M |
EBITDA | -59.74M |
EBIT | -59.91M |
Earnings Per Share (EPS) | -$1.81 |
Balance Sheet
The company has $159.09 million in cash and $11.71 million in debt, giving a net cash position of $147.37 million or $4.28 per share.
Cash & Cash Equivalents | 159.09M |
Total Debt | 11.71M |
Net Cash | 147.37M |
Net Cash Per Share | $4.28 |
Equity (Book Value) | -197.13M |
Book Value Per Share | -5.73 |
Working Capital | 150.67M |
Cash Flow
In the last 12 months, operating cash flow was -$47.72 million and capital expenditures -$134,000, giving a free cash flow of -$47.85 million.
Operating Cash Flow | -47.72M |
Capital Expenditures | -134,000 |
Free Cash Flow | -47.85M |
FCF Per Share | -$1.39 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
BioAge Labs does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | -10.03% |
FCF Yield | -7.73% |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |